Cost of ADHD treatment using methylphenidate and atomoxetine in the South African private healthcare sector

• Published in: Expert review of pharmacoeconomics & outcomes research Vol. 19; no. 6; p. 677
• Main Authors: Munasur-Naidoo, A P, Truter, I
• Format: Journal Article
• Language: English
• Published: England 02.11.2019
• Subjects: Adrenergic Uptake Inhibitors - administration & dosage; Adrenergic Uptake Inhibitors - economics; Atomoxetine Hydrochloride - administration & dosage; Atomoxetine Hydrochloride - economics; Attention Deficit Disorder with Hyperactivity - drug therapy; Attention Deficit Disorder with Hyperactivity - economics; Central Nervous System Stimulants - administration & dosage; Central Nervous System Stimulants - economics; Humans; Methylphenidate - administration & dosage; Methylphenidate - economics; Private Sector - economics; South Africa; South Africa; methylphenidate; South Africa; cost; drug utilization; Attention-Deficit/Hyperactivity Disorder (ADHD)
• ISSN: 1744-8379
• DOI: 10.1080/14737167.2019.1661776

: The prevalence of Attention-Deficit/Hyperactivity Disorder (ADHD) has risen over the last two decades, with a corresponding increase in the cost of its medication. Drug utilization studies in South Africa focusing on ADHD are limited. : The primary aim was to determine the cost of methylphenidate and atomoxetine (used for ADHD). The Intercontinental Marketing Service (IMS) database which contains data of the private healthcare sector was interrogated from 2013 to 2016 (48-month period) focussing on methylphenidate and atomoxetine. Drug consumption was expressed in number of DDDs, DDDs/1000 inhabitants/day and cost in Rands. : Methylphenidate-containing products constituted a considerably higher percentage of the market share when compared to atomoxetine (90.30% versus 9.70%). The DDD/1000 inhabitants/day for methylphenidate was 6.010 with an annual cost for R266 691 778 in 2013, which increased to 7.827 DDDs/1000 inhabitants/day with an annual cost of R436 041 506 in 2016. Consumption of both methylphenidate and atomoxetine increased from 2013 to 2016. There was a preference for long-acting extended-release methylphenidate tablets even though the unit costs were higher when compared to the short-acting formulations. Despite increases in unit costs, the spend in South Africa showed an upward trend for methylphenidate and atomoxetine.